The FreeStyle Libre family of products

Better diabetes 
self-management 

Clinical benefits for a broad range of T1D and T2D patients. 

Increased glucose monitoring frequency is strongly associated with better diabetes self-management* 

Overall, 0.9% A1C reduction in patients with T2D6*

(p<0.0001)

44% increase in time in target range 

(3.9-10.0 mmol/L) from 11.7 to 16.8 hours a day with increased scan rate5* (p<0.001) 

63% reduction in time spent in hyperglycemia

across patients with T1D and T2D5* (p<0.001)

43% reduction in time spent in hypoglycemia

in patients with T2D2* (p<0.001)

The FreeStyle Libre family of products helps patients with T2D make better choices  

98% of patients with T2D using the system:9*

  • Understand the impact of their actions on their glucose levels

  • Feel more engaged with managing their diabetes

Lifestyle modifications can help lower A1C 

  • Patients with T2D who make lifestyle changes, such as diet and physical activity, see improved glucose control10*

Watch this video to learn more about how patients can apply what

 they learn from their scans into their daily life.

 

Increased time in range by 1 hour/day12* (3.9-10.0 mmol/L) 

Reduced A1C by 0.4%11* 

Increased the frequency of glucose monitoring to an average of 13X per day vs. SMBG.11*†

Reduced time spent in hyperglycemia

(>10 mmol/L) by 1 hr/day with no significant increase in time spent in hypoglycemia (<3.9 mmol/L)11*

90% of children and teenagers agreed that the FreeStyle Libre 2 system did not get in the way of daily activities11* 

Continuing health 

education 

Explore upcoming virtual and in-person educational events. 

SMBG=self-monitoring of blood glucose; T1D=type 1 diabetes; T2D=type 2 diabetes.

* Data from this study were collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system with optional real-time glucose alarms. Therefore, the study data are applicable to both products.

† Results from the SELFY study of diabetes self-management in children (4-12 years) and teenagers (13-17 years). Questionnaire was either completed by children or their caregiver. 

 

References:

  1. Bolinder J, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388(10057):2254-63.
  2. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73.
  3. Ajjan R. Insights from real world use of flash continuous glucose monitoring. Symposium presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
  4. Seibold A, et al. A meta-analysis of real-world observational studies on the impact of flash glucose monitoring on glycemic control as measured by A1C. Poster presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
  5. Lang J, et al. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control [Abstract 089]. Diabetes Technol Ther 2019;21(1):A–40.
  6. Kröger J, et al. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. Diabetes Ther 2020;11(1):279-91.
  7. Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther 2019;21(2):81-85.
  8. Beck RW, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 2019;42(3):400-05.
  9. Data on file, Abbott Diabetes Care Inc.
  10. Yaron M, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care 2019;42(7):1178-84.
  11. Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 2018;19(7):1294-301.
  12. Berard L, Virdi N, Dunn TC. Canadian realworld analysis of flash glucose monitoring and impact on glycemic control. Poster presented at: Diabetes Canada Conference; October 2-5, 2019; Winnipeg, MB.

Cookie Policy

FreeStyle Libre uses cookies to give you the best possible service. By using our website, you consent to the use of cookies. 

Data protection

This site is intended for Canadian Healthcare Professionals only. Visit patient site.

The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/insert. 

The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.